- /
- Supported exchanges
- / US
- / ATRA.NASDAQ
Atara Biotherapeutics Inc (ATRA NASDAQ) stock market data APIs
Atara Biotherapeutics Inc Financial Data Overview
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Atara Biotherapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Atara Biotherapeutics Inc data using free add-ons & libraries
Get Atara Biotherapeutics Inc Fundamental Data
Atara Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 3 965 K
- EBITDA: 838 K
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Atara Biotherapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-10
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atara Biotherapeutics Inc News
New
Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, following the pl...
Atara Announces Departure Of Carol Gallagher As Director, Brian Cherry To Succeed
(RTTNews) - Atara Biotherapeutics, Inc. (ATRA), a clinical-stage biotechnology company, announced the departure of Carol Gallagher from its Board of Directors and appointed Brian Cherry to succeed her...
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 202...
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.